胆碱酯酶抑制药与痴呆的治疗

被引：5

作者：

孙洪吉

解恒革

机构：

[1] 解放军总医院南楼神经内科

来源：

临床药物治疗杂志 | 2012年 / 10卷 / 02期

关键词：

胆碱酯酶抑制药; 阿尔茨海默病; 血管性痴呆; 路易体痴呆; 帕金森病痴呆;

D O I：

暂无

中图分类号：

R749.1 [脑器质性精神障碍];

学科分类号：

100205 ;

摘要：

胆碱酯酶抑制药是近20年来治疗痴呆的主要药物。虽然人们一直在开发其他类型的痴呆治疗药物,但是迄今为止仍未取得重大临床突破。目前应用的胆碱酯酶抑制代表药物有多奈哌齐(donepezil)、利斯的明(rivastigmine)、加兰他敏(galantamine)以及石杉碱甲(huperzine A)等。本文主要概述了胆碱酯酶抑制药在阿尔茨海默病、血管性痴呆、路易体痴呆和帕金森病痴呆中的临床研究进展,为临床应用此类药物提供参考。

引用

页码：1 / 6

页数：6

共 13 条

[1] A phase II trial of huperzine A in mild to moderate Alzheimer disease [J].

Rafii, M. S. ;

Walsh, S. ;

Little, J. T. ;

Behan, K. ;

Reynolds, B. ;

Ward, C. ;

Jin, S. ;

Thomas, R. ;

Aisen, P. S. .

NEUROLOGY, 2011, 76 (16) :1389-1394

[2] Efficacy of Rivastigmine on Executive Function in Patients with Parkinson's Disease Dementia [J].

Schmitt, Frederick A. ;

Farlow, Martin R. ;

Meng, Xiangyi ;

Tekin, Sibel ;

Olin, Jason T. .

CNS NEUROSCIENCE & THERAPEUTICS, 2010, 16 (06) :330-336

[3]

Randomized, Placebo-Controlled, Clinical Trial of Donepezil in Vascular Dementia: Differential Effects by Hippocampal Size[J] . Gustavo C. Román,Stephen Salloway,Sandra E. Black,Donald R. Royall,Charles DeCarli,Michael W. Weiner,Margaret Moline,Dinesh Kumar,Rachel Schindler,Holly Posner.Stroke . 2010 (6)

[4]

Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial[J] . Lancet Neurology . 2009 (1)

[5] Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial) [J].

Litvinenko I.V. ;

Odinak M.M. ;

Mogil'naya V.I. ;

Emelin A.Y.U. .

Neuroscience and Behavioral Physiology, 2008, 38 (9) :937-945

[6]

Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson’s Disease Dementia[J] . Wolfgang Oertel,Werner Poewe,Erik Wolters,Peter Paul Deyn,Murat Emre,Courtney Kirsch,Chuanchieh Hsu,Sibel Tekin,Roger Lane.Drug Safety . 2008 (1)

[7]

Galantamine treatment of vascular dementia: A randomized trial[J] . A P. Auchus,H R. Brashear,S Salloway,A D. Korczyn,P P. De Deyn,C Gassmann-Mayer.Neurology . 2007 (5)

[8]

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study[J] . The Lancet . 2006 (9516)

[9] Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease [J].

Dujardin, Kathy ;

Devos, David ;

Duhem, Stephane ;

Destee, Alain ;

Marie, Rose-Marie ;

Durif, Franck ;

Lacomblez, Lucette ;

Touchon, Jacques ;

Pollak, Pierre ;

Pere, Jean-Jacques .

JOURNAL OF NEUROLOGY, 2006, 253 (09) :1154-1159

[10]

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: A 26-week, multicenter, open-label study[J] . Jeffrey L. Cummings,Barbara Koumaras,Michael Chen,Dario Mirski.American Journal of Geriatric Pharmacotherapy . 2005 (3)

← 1 2 →